Haleos Labs Q1 Results: Standalone Profit Rises 45% QoQ To ₹3.24 Cr
Haleos Labs Limited posted a standalone net profit of ₹3.24 crore in Q1FY27, up 45% QoQ, aided by inventory benefits. Consolidated profit fell 58% YoY to ₹2.65 crore due to higher material costs. The Board approved director re-appointments and MD remuneration revision, with the AGM set for September 30, 2026.
*this image is generated using AI for illustrative purposes only.
Haleos Labs Limited reported a standalone net profit of ₹3.24 crore for the quarter ended June 30, 2026 (Q1FY27), marking a 45% increase from ₹2.23 crore in the preceding quarter. The improvement was primarily driven by a reduction in inventory costs, which contributed a negative expense of ₹7.83 crore, compared to ₹7.34 crore in March 2026. However, consolidated net profit attributable to equity holders declined 58% year-on-year to ₹2.65 crore from ₹4.16 crore in Q1FY26, reflecting higher material costs and lower operational revenue.
The Board of Directors held its 98th meeting on August 5, 2026, to approve the unaudited standalone and consolidated financial results as reviewed by the Audit Committee and statutory auditors Rambabu & Co. In compliance with Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company submitted these results to the BSE and NSE. The financial statements were prepared in accordance with Ind AS 34 and other generally accepted accounting principles in India.
Key Financial Metrics
| Metric | Standalone (₹ Lakh) | Consolidated (₹ Lakh) |
|---|---|---|
| Revenue From Operations | 6,782.97 | 7,294.23 |
| Total Revenue | 6,828.58 | 7,340.56 |
| Total Expenses | 6,300.99 | 6,996.59 |
| Profit Before Tax | 527.59 | 343.97 |
| Net Profit | 323.78 | 184.03 |
| EPS (Basic/Diluted) | ₹10.71 | ₹8.75 |
Standalone revenue from operations rose 7% quarter-on-quarter to ₹67.83 crore but fell 14% year-on-year from ₹79.04 crore. Other income decreased significantly to ₹45.61 lakh from ₹100.94 lakh in the same period last year. On a consolidated basis, revenue from operations dropped 12% YoY to ₹72.94 crore. The subsidiary, Mahi Drugs Private Limited, reported a total revenue of ₹10.25 crore and a net loss after tax of ₹20.16 crore for the quarter, which management stated was not material to the Group.
Corporate Governance Actions
The Board approved several key governance matters subject to shareholder approval at the upcoming Annual General Meeting. These include the re-appointment of Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam as Independent Directors for a second term of five years, effective November 13, 2026. Additionally, the Board sought approval for a revision in managerial remuneration for TVVSN Murthy, Managing Director.
The company scheduled its 20th Annual General Meeting for September 30, 2026, to be held via Video Conferencing or Other Audio Visual Means, in accordance with MCA General Circular No. 03/2025 and No. 09/2024. A detailed report pursuant to Schedule III of the SEBI LODR Regulations will be filed separately within the prescribed timeline.
What the Numbers Show
The divergence between standalone and consolidated performance highlights cost pressures in the supply chain. While standalone profitability improved due to inventory write-downs, consolidated margins faced headwinds from rising material costs, which increased to ₹40.14 crore from ₹27.73 crore year-on-year. This suggests that while Haleos Labs managed its own inventory efficiently, broader group-level input costs remain elevated, impacting overall bottom-line growth despite stable operational volumes.
Historical Stock Returns for Haleos
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -9.00% | -8.75% | -13.54% | +8.79% | +27.68% | +90.37% |
How does Haleos Labs plan to mitigate the impact of rising material costs, which increased significantly year-on-year, on its consolidated margins in upcoming quarters?
What is the strategic rationale behind the proposed revision in managerial remuneration for the Managing Director, and how might it influence executive performance incentives?
Given the significant net loss reported by subsidiary Mahi Drugs Private Limited, what corrective measures or restructuring plans is the board considering to improve its contribution to the group?
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
